Respiratory Syncytial Virus (RSV) Infection

Overview

Plain-Language Overview

Respiratory Syncytial Virus (RSV) Infection is a common viral illness that primarily affects the lungs and breathing passages. It mainly causes symptoms like coughing, wheezing, and difficulty breathing, especially in young children and older adults. The infection can lead to inflammation and swelling in the small airways of the lungs, making it harder to breathe. It often starts with cold-like symptoms but can progress to more serious lung problems such as bronchiolitis or pneumonia. This condition is highly contagious and spreads through droplets when an infected person coughs or sneezes. The main health impact is on the respiratory system, where it can cause significant breathing difficulties.

Clinical Definition

Respiratory Syncytial Virus (RSV) Infection is an acute viral infection caused by the RSV, a single-stranded RNA virus of the Paramyxoviridae family. It primarily targets the respiratory epithelium, causing inflammation and necrosis of the bronchiolar lining cells, leading to bronchiolitis and sometimes pneumonia. The infection is most severe in infants, young children, elderly patients, and immunocompromised individuals. The pathophysiology involves viral replication in the airway epithelium, resulting in mucus production, airway obstruction, and impaired gas exchange. Clinically, it presents with cough, tachypnea, wheezing, and hypoxia. RSV is a major cause of hospitalization for lower respiratory tract infections in infants worldwide and is a significant cause of morbidity and mortality in vulnerable populations.

Inciting Event

Inhalation of aerosolized RSV particles from infected individuals initiates infection.
Close contact with respiratory secretions during RSV season triggers transmission.
Nosocomial exposure in hospital or daycare settings can precipitate infection.

Latency Period

The incubation period is typically 4 to 6 days after exposure to RSV.
Symptoms usually develop within 1 week of viral acquisition.

Diagnostic Delay

Early symptoms mimic common viral upper respiratory infections, leading to misattribution to mild cold.
Lack of specific rapid testing in outpatient settings delays definitive diagnosis.
Overlap with other viral pathogens causes diagnostic uncertainty without confirmatory testing.

Clinical Presentation

Signs & Symptoms

Runny nose and congested nasal passages as early upper respiratory symptoms
Cough that progresses to wheezing and respiratory distress
Fever usually low-grade but can be higher in infants
Poor feeding and irritability in infants due to respiratory discomfort
Apnea episodes especially in premature infants or those under 6 weeks old

History of Present Illness

Initial symptoms include rhinorrhea, cough, and low-grade fever lasting 1-3 days.
Progression to wheezing, tachypnea, and increased work of breathing occurs over several days.
Severe cases develop hypoxia, nasal flaring, and retractions indicating lower airway involvement.
Apnea episodes may be present in young infants or high-risk patients.

Past Medical History

History of prematurity or bronchopulmonary dysplasia increases risk of severe disease.
Previous congenital heart disease or chronic lung conditions worsen clinical course.
Prior episodes of wheezing or reactive airway disease may be noted.
Immunodeficiency or recent immunosuppressive therapy predisposes to severe infection.

Family History

Family history of atopy or asthma may be present but is not directly linked to RSV susceptibility.
No specific heritable syndromes are associated with increased RSV infection risk.
Household contacts with recent respiratory infections increase exposure risk.

Physical Exam Findings

Wheezing and crackles on lung auscultation indicating airway obstruction and inflammation
Tachypnea with use of accessory muscles reflecting respiratory distress
Nasal flaring and intercostal retractions as signs of increased work of breathing
Hypoxemia evidenced by cyanosis or low oxygen saturation on pulse oximetry
Prolonged expiratory phase due to bronchospasm and mucus plugging

Diagnostic Workup

Diagnostic Criteria

Diagnosis of RSV infection is established by detecting the virus in respiratory secretions using rapid antigen detection tests, polymerase chain reaction (PCR) assays, or viral culture. Clinical suspicion arises in patients with acute onset of cough, wheezing, and respiratory distress, especially during RSV season. Chest radiographs may show hyperinflation and patchy infiltrates but are not diagnostic. Confirmatory diagnosis relies on positive identification of RSV antigen or RNA from nasal swabs or aspirates. Serologic testing is less commonly used due to delayed antibody response.

Pathophysiology

Key Mechanisms

RSV infects respiratory epithelial cells, causing cell death and sloughing that leads to airway obstruction.
The host immune response triggers inflammation and mucus production, contributing to airway narrowing and wheezing.
Infected cells release cytokines and chemokines that recruit immune cells, exacerbating airway edema and bronchospasm.
RSV causes bronchiolitis by obstructing small airways with cellular debris and mucus plugs.
Impaired mucociliary clearance due to epithelial damage facilitates viral spread and secondary bacterial infection.

Involvement	Details
Organs	Lungs are the primary organs affected, with inflammation causing bronchiolitis and pneumonia.
Organs	Nasal passages serve as the initial site of viral entry and replication, contributing to upper respiratory symptoms.
Tissues	Bronchial mucosa is inflamed and damaged during RSV infection, leading to airway obstruction and wheezing.
Tissues	Alveolar tissue may be involved in severe cases, causing impaired gas exchange and hypoxia.
Cells	Respiratory epithelial cells are the primary site of RSV infection and viral replication.
	Alveolar macrophages contribute to the immune response by phagocytosing infected cells and releasing cytokines.
	T lymphocytes mediate adaptive immune responses that help clear RSV infection but may also contribute to airway inflammation.
Chemical Mediators	Interleukin-8 (IL-8) recruits neutrophils to the site of infection, contributing to airway inflammation.
	Tumor necrosis factor-alpha (TNF-α) promotes inflammation and fever during RSV infection.
	Interferon-gamma (IFN-γ) enhances antiviral immunity by activating macrophages and promoting viral clearance.

Treatments

Pharmacological Treatments

Ribavirin
- Mechanism:
  - Inhibits viral RNA synthesis by acting as a nucleoside analog, interfering with viral replication.
- Side effects:
  - Hemolytic anemia
  - Teratogenicity
  - Bronchospasm
- Clinical role:
  - Second-line
Palivizumab
- Mechanism:
  - Monoclonal antibody targeting the RSV F protein, preventing viral entry into host cells.
- Side effects:
  - Injection site reactions
  - Fever
  - Hypersensitivity reactions
- Clinical role:
  - Prophylactic

Non-pharmacological Treatments

Supportive care with oxygen supplementation to maintain adequate oxygenation in hypoxic patients.
Hydration and nasal suctioning to relieve airway obstruction and improve respiratory function.
Mechanical ventilation in severe cases with respiratory failure or apnea.

Prevention

Pharmacological Prevention

Palivizumab, a monoclonal antibody targeting RSV F protein, for high-risk infants
RSV immunoglobulin used rarely for prophylaxis in select populations
No effective vaccine currently available for routine RSV prevention
Supportive use of antipyretics to manage fever during infection
No role for routine antiviral therapy in prophylaxis

Non-pharmacological Prevention

Hand hygiene to reduce transmission of RSV in community and healthcare settings
Avoidance of exposure to crowds and sick contacts during RSV season for high-risk infants
Breastfeeding to provide passive immunity and reduce severity of infection
Environmental cleaning of surfaces and toys to limit viral spread
Use of masks and respiratory etiquette to prevent droplet transmission

Outcome & Complications

Complications

Bronchiolitis causing airway obstruction and hypoxia
Secondary bacterial pneumonia due to impaired mucociliary clearance
Respiratory failure requiring mechanical ventilation in severe cases
Apnea and sudden respiratory arrest in high-risk infants
Otitis media as a common concurrent infection

Short-term Sequelae	Long-term Sequelae
Prolonged cough and wheezing lasting weeks after acute illness Hypoxemia requiring supplemental oxygen during hospitalization Feeding difficulties leading to dehydration and weight loss Hospitalization for respiratory support in severe bronchiolitis Transient reactive airway hyperresponsiveness post-infection	Increased risk of recurrent wheezing and asthma in childhood Chronic airway hyperreactivity persisting after infection resolution Potential development of bronchiectasis in severe or repeated infections Impaired lung function in children with severe early RSV disease Increased susceptibility to future respiratory infections

Differential Diagnoses

Respiratory Syncytial Virus (RSV) Infection versus Influenza Virus Infection

Respiratory Syncytial Virus (RSV) Infection	Influenza Virus Infection
Primarily affects infants and young children under 2 years	More common in older children and adults
Gradual onset with wheezing, cough, and low-grade fever	Abrupt onset with high fever, myalgia, and systemic symptoms
Paramyxovirus family	Orthomyxovirus family
Supportive care; antivirals like ribavirin rarely used	Responds to neuraminidase inhibitors like oseltamivir

Respiratory Syncytial Virus (RSV) Infection versus Bacterial Bronchiolitis (e.g., Staphylococcus aureus)

Respiratory Syncytial Virus (RSV) Infection	Bacterial Bronchiolitis (e.g., Staphylococcus aureus)
Lymphocytic predominance and negative bacterial cultures	Elevated neutrophils and positive bacterial cultures
Gradual onset with wheezing and mild fever	Rapid progression with high fever and purulent sputum
No improvement with antibiotics; supportive care preferred	Improves with antibiotics targeting common bacteria

Respiratory Syncytial Virus (RSV) Infection versus Human Metapneumovirus Infection

Respiratory Syncytial Virus (RSV) Infection	Human Metapneumovirus Infection
Respiratory syncytial virus, Paramyxoviridae family	Metapneumovirus genus, Paramyxoviridae family
Most severe in infants under 2 years	Common in children under 5 years but can affect older children
More frequent and severe wheezing and bronchiolitis	Similar symptoms but often milder wheezing and less severe bronchiolitis

Respiratory Syncytial Virus (RSV) Infection versus Pertussis (Whooping Cough)

Respiratory Syncytial Virus (RSV) Infection	Pertussis (Whooping Cough)
Wheezing and cough without classic whooping sound	Paroxysmal coughing fits with inspiratory whoop and posttussive vomiting
Exposure to young children in daycare or family settings	Exposure to unvaccinated or incompletely vaccinated individuals
Positive PCR or antigen test for respiratory syncytial virus	Positive PCR or culture for Bordetella pertussis

Respiratory Syncytial Virus (RSV) Infection versus Asthma Exacerbation

Respiratory Syncytial Virus (RSV) Infection	Asthma Exacerbation
First episode or isolated bronchiolitis in infants	Recurrent episodes triggered by allergens or irritants
Typically affects infants under 2 years	Usually presents after 2 years of age with chronic symptoms
Limited response to bronchodilators; supportive care emphasized	Improves with bronchodilators and corticosteroids